← Markets

Immunovant, Inc.

IMVT · NASDAQ

Market closed$40.26$1.30 (+3.34%)After hours $39.92 · -0.84%

Key statistics

Previous close$38.96
Open$38.33
Day high$40.46
Day low$38.01
52-week high$41.23
52-week low$14.32
Market cap8.27B
Volume852.56K
Average volume1.83M
P/E ratio-15.08
Forward P/E—
EPS-2.67
Dividend yield0.00%

Market context

Why it moved

Immunovant (IMVT) shares rose sharply today, likely driven by renewed investor interest in the biotechnology sector and positive momentum in clinical-stage immunology companies with promising pipeline catalysts.

StocktwitsStocktwitsStocktitanInstagramInstagram

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Immunovant shares gained, approaching their 52-week high of $41.23, as the broader biotech sector found support from UBS upgrading healthcare to a key allocation theme — citing improving fundamentals, a stabilizing regulatory environment, and an active M&A backdrop benefiting biotech. One source noted IMVT has risen roughly 3.6% since its last earnings report, with investor focus trained on upcoming clinical data and regulatory updates for its FcRn inhibitor pipeline. The move came despite a broader tech-driven pullback in the S&P 500, suggesting relative resilience in biopharma names.

3.3368

July 17, 2026Immunovant shares declined amid a broader pullback in biotech and growth stocks, as the Nasdaq slid on tech weakness and AI valuation concerns. Source 33 references a recent session where IMVT surged despite a wider-than-expected quarterly loss, reflecting investor focus on pipeline progress over near-term earnings — a dynamic that continues to define sentiment around the FcRn inhibitor developer. Volume came in well below average, suggesting limited conviction behind today's move, while the broader healthcare sector (XLV) also faced pressure before recovering in after-hours trade.

-2.3069

July 14, 2026Immunovant declined alongside broader market weakness as U.S.-Iran tensions sent oil prices surging and pressured equities broadly, while the healthcare sector (XLV) also closed lower. Investor focus remains on pipeline catalysts for lead asset IMVT-1402, with multiple analysts maintaining bullish stances — LifeSci Capital reaffirmed a Buy/$53 target, BofA set a $43 target citing $6.8B peak sales potential, and Stifel holds a $49 target — underpinned by strong Phase 2 RA data showing 72.7% ACR20 response rates. Recent insider share sales by the CTO, COO, and CLO were mandated RSU tax-withholding transactions, not discretionary sells.

-2.5434

July 10, 2026Immunovant fell sharply, giving back some of the gains from its recent 52-week high surge driven by strong Phase 2 IMVT-1402 rheumatoid arthritis data. Multiple insider sales disclosed today — the COO, CTO, and Chief Legal Officer each sold shares on July 8 in RSU tax-withholding transactions — may be weighing on sentiment, even as LifeSci Capital raised its price target to $53 (from $45) with a Buy rating just yesterday. The broader healthcare sector (XLV) also softened, compounding the pullback for this pre-revenue clinical-stage biotech.

-3.3585

July 10, 2026Immunovant closed near its 52-week high, buoyed by a fresh analyst upgrade from LifeSci Capital, which raised its price target to $53 (from $45) while maintaining a Buy rating — the most bullish target on the Street alongside Stifel's $49. The positive sentiment reflects strong Phase 2 data for lead candidate IMVT-1402, which showed ACR20 response rates above 70% in refractory rheumatoid arthritis, prompting multiple target hikes from BofA ($43) and H.C. Wainwright ($40) as well. Shares have now surged roughly 130% over the past year, and biotech sector tailwinds — including Jim Cramer calling the group the 'hottest in the market' amid a pickup in M&A activity — provided additional support.

1.935

July 8, 2026Immunovant surged nearly 4%, touching a new 52-week high of $40.77, driven by sustained analyst enthusiasm around lead candidate IMVT-1402 and a broadly bullish backdrop for biotech. Multiple analysts have recently raised price targets — BofA to $43, H.C. Wainwright to $40, and Stifel to $49 — following compelling Phase 2 rheumatoid arthritis data showing 72.7% ACR20 response rates, while Jim Cramer called biotech the 'hottest group in the market' amid a favorable M&A and regulatory environment. The healthcare sector (XLV) also touched a fresh 52-week high, amplifying momentum for the name.

3.8601

July 3, 2026Immunovant closed up nearly 2% and is extending gains over 3% in after-hours trading, approaching its 52-week high of $39.28, as healthcare emerged as the strongest S&P sector on the day amid a soft June jobs report that dampened rate-hike expectations. Investor attention is also on the CTO's recent sale of 53% of his shares (~$1.5M) and a broader backdrop of mixed analyst sentiment—consensus target of ~$46 implies meaningful upside—alongside lingering pipeline questions following batoclimab's Phase 3 failure in thyroid eye disease in April and JPMorgan's May price target raise to $47.

1.7042

July 2, 2026Immunovant shares declined modestly, trading near their 52-week high, as an insider sale of ~$1.5M in shares (reported June 29) tempered near-term sentiment even as the analyst community remains constructive — Citigroup recently raised its price target to $61 (Buy) and JPMorgan lifted its target to $47 (Overweight). Competitive dynamics in thyroid eye disease are a key watchpoint after rival Viridian Therapeutics received FDA approval for Lumvoa, while IMVT's own Phase 3 TED studies failed in early April. With the stock up over 50% year-to-date, investors appear to be weighing the pipeline setback and insider activity against bullish analyst conviction.

-1.0122

Moomoo · July 9, 2026LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $53Simply Wall Street · June 19, 2026Immunovant (IMVT) Is Up 7.5% After Batoclimab Shows Phase IIb CIDP Benefit - What's ChangedInvestor's Business Daily · May 20, 2026These Two Biotech Stocks Rocketed — And One Just Broke OutQuiver Quantitative · May 20, 2026Immunovant jumps 30.8% on upbeat IMVT-1402 rheumatoid arthritis update | IMVT Stock Newspharmaphorum · April 17, 2026Immunovant's thyroid eye disease drug flunks pivotal trialsStock Titan · April 2, 2026Two late-stage thyroid eye disease trials miss for Immunovant
Benzinga · June 30, 2026Citigroup Maintains Buy on Immunovant, Raises Price Target to $61
Mt Newswire · June 29, 2026Immunovant Insider Sold Shares Worth $1,532,309, According to a Recent SEC Filing
Mt Newswire · May 26, 2026JPMorgan Raises Immunovant Price Target to $47 From $35, Overweight Rating Kept
Benzinga · May 26, 2026Guggenheim Maintains Buy on Immunovant, Raises Price Target to $62
Benzinga · May 22, 2026Truist Securities Maintains Hold on Immunovant, Raises Price Target to $30
Benzinga · May 21, 2026These Analysts Increase Their Forecasts On Immunovant After Q4 Results
Benzinga · May 21, 2026B of A Securities Maintains Buy on Immunovant, Raises Price Target to $43
Benzinga · May 20, 2026Immunovant Stock Surges Despite Disappointing Earnings Miss

Peers

S&P 500SPX · $7,457.69-1.01%argenx SEARGX · $860.55+0.30%Roivant Sciences Ltd.ROIV · $34.51+1.71%Moderna, Inc.MRNA · $61.82-2.11%Crinetics Pharmaceuticals, Inc.CRNX · $83.86-0.06%Recursion Pharmaceuticals, Inc.RXRX · $2.95-2.48%AlvotechALVO · $3.46+2.67%NewAmsterdam Pharma Company N.V.NAMS · $31.68+2.03%Kymera Therapeutics, Inc.KYMR · $115.77+1.56%TG Therapeutics, Inc.TGTX · $54.87-0.11%Protagonist Therapeutics, Inc.PTGX · $140.91+6.73%Cogent Biosciences, Inc.COGT · $39.08+3.00%